Vaxcyte’s VAX-31 vaccine meets primary endpoints in phase 3 trial

🌐 Investing.com (Cyprus) —
Vaxcyte’s VAX-31 vaccine meets primary endpoints in phase 3 trial

AI Summary

Vaxcyte said its VAX-31 vaccine met the primary endpoints in a Phase 3 clinical trial. The result marks a late-stage clinical milestone, though the title gives no efficacy or safety figures.

Markets Health Vaxcyte VAX-31 vaccine Phase 3 trial clinical endpoints biotechnology

Read original source →